Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study

Journal of Viral Hepatitis

Volumn 17, Issue 6, 2010, Pages 427-434

  Morisco, F ^a   Stroffolini, T ^b   Medda, E ^c   Amoruso, D C ^a   Almasio, P L ^d   Villa, E ^e   Zuin, M ^f   Paris, B ^g   Stanzione, M ^h   Caporaso, N ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g Esine Hospital   (Italy)

^h SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Body mass index; Cirrhosis; Hepatitis C virus; Nonresponder; Pegylated interferon; Relapser

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; VIRUS RNA;

AGED; ARTICLE; BODY MASS; CLEARANCE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADULT; AGE; BLOOD; CLASSIFICATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MEDICATION COMPLIANCE; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT FAILURE; VIROLOGY;

ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; ITALY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; RNA, VIRAL; TREATMENT FAILURE;

EID: 77952273990     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01200.x     Document Type: Article

References (39)

1. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001 358 : 958 965.
2. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
3. Taliani G, Gemignani G, Ferrari C et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin non responders patients. Gastroenterology 2006 130 : 1098 1106.
4. Schiffman ML, Di Bisceglie AM, Lindsay KL et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004 126 : 1015 1023.
5. Sherman M, Yoshida EM, Deschênes M et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006 55 : 1631 1638.
6. Akobeng AK. Assessing the validity of clinical trials. J Pediatr Gastroenterol Nutr 2008 47 : 277 282.
7. Rothwell PM. External validity of randomized controlled trials: to whom do the results apply? Lancet 2005 365 : 82 93.
8. Bergmann JF, Vrolijk JM, van der Schaar P et al. Gamma- glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. Liver Int 2007 27 : 1217 1225.
9. Ciancio A, Picciotto A, Giordanino C et al. A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Aliment Pharmacol Ther 2006 24 : 1079 1086.
10. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 123 : 1061 1098.
11. Anand BS, Currie S, Dieperink E et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006 130 : 1607 1616.
12. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009 32 (Suppl. 1 S13 S61.
13. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981 1 : 431 435.
14. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696 699.
15. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996 24 : 289 293.
16. Kleiner DE, Brunt EM, Van Natta M et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 41 : 1313 1321.
17. Weight and Waist Measurement: Tools for Adults. National Institute of Diabetes and Digestive and Kidney Disease. NIH. Pubblication No. 04-5283, November 2008. http://wim.middk.mih.gov (accessed on 16 March 2009).
18. Sherman M, Shafran S, Burak K et al. Management of chronic hepatitis C: Consensus guidelines. Can J Gastroenterol 2007 21 (Suppl. C 25C 34C. (Pubitemid 47177083)
19. Krawitt EL, Ashikaga T, Gordon SR et al. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 2005 43 : 243 249.
20. Jacobson IM, Gonzalez SA, Ahmed F et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005 100 : 2453 2462.
21. Mathew A, Peiffer LP, Rhoades K, McGarrity T. Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment. Dig Dis Sci 2006 51 : 1956 1961.
22. Maynard M, Pradat P, Bailly F et al. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies. J Hepatol 2006 44 : 484 490.
23. Moucari R, Ripault MP, Oulès V et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 2007 46 : 596 604.
24. Diago M, Crespo J, Olveira A et al. Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. Aliment Pharmacol Ther 2007 26 : 1131 1138.
25. Cheruvattath R, Rosati MJ, Gautam M et al. Pegylated interferon and ribavirin failures: is retreatment an option? Dig Dis Sci 2007 52 : 732 736.
26. Hadziyannis SJ, Sette Jr. H, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
27. Rizzetto M, Colombo M, Ascione A et al. Effectiveness of hepatitis C virus treatment in real-life practice: a prospective obeservational multicenter study in Italy (Probe). J Hepatol 2008 48 (Suppl. 2 S311.
28. Rosina F, Tosti ME, Borghesio E et al. PEG-IFN for hepatitis C in clinical practice. Dig Liv Dis 2009 41 : A7.
29. Herrine SK, Brown Jr. RS, Bernstein DE, Ondovik MS, Lentz E, Te H. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. Dig Dis Sci 2005 50 : 719 726.
30. Basso M, Torre F, Grasso A et al. A pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. Dig Liv Dis 2007 39 : 47 51.
31. Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004 350 : 2265 2271.
32. Conjeevaram HS, Fried MW, Jeffers LJ et al., Virahep-C Study Group Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006 131 : 470 477.
33. Persico M, Capasso M, Persico E et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 2007 46 : 1009 1015.
34. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006 43 : 1177 1186.
35. Reddy KR, Govindarajan S, Marcellin P et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon a-2a plus ribavirin. J Viral Hepat 2008 15 : 129 136.
36. Fujita N, Sugimoto R, Urawa N et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J Gastroenterol Hepatol 2007 22 : 1886 1893.
37. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of U.S. Veterans to treatment for the hepatitis C virus. Hepatology 2007 46 : 37 47.
38. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999 19 (Suppl. 1 17 24.
39. Tanioka D, Iwasaki Y, Araki Y et al. Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience. Liver Int 2009 29 : 721 729.